Yahoo · Oct 2, 2026
Delta Stock Struggles As Revenue Growth Accelerates; Will Its Results Pass Muster?
Despite accelerating revenue growth, Delta stock is struggling to reclaim its 50-day line ahead of its Q3 earnings report.
AN
NASDAQ · ANGO
AngioDynamics, Inc.
Healthcare · Medical - Instruments & Supplies
$14.19
Down-$0.23 (-1.60%)
Updated Oct 8, 2026, 12:34 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 471.53M
- P/E ratio
- -17.09
- Dividend yield
- 0.00%
- 52-week range
- $9.39 – $16.29
- Volume
- 1.01M
- Avg. volume
- 570.39K
Price performance · ANGO
ANGO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
ANGO closed at $14.19 after 21 trading sessions, down 7.38% for the selected period.
- Last close
- $14.19
- Period change
- -7.38%
- Period low
- $14.19
- Period high
- $15.68
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $14.20 | $14.51 | $14.13 | $14.19 | 1.01M |
| Oct 6, 2026 | $15.61 | $15.655 | $14.23 | $14.42 | 847.58K |
| Oct 5, 2026 | $15.02 | $15.63 | $14.92 | $15.54 | 636.17K |
| Oct 2, 2026 | $15.355 | $15.355 | $15.00 | $15.11 | 1.13M |
| Oct 1, 2026 | $15.36 | $15.52 | $14.96 | $15.12 | 685.13K |
| Sep 30, 2026 | $15.65 | $15.66 | $15.33 | $15.38 | 634.48K |
| Sep 29, 2026 | $15.54 | $15.625 | $14.89 | $15.60 | 862.1K |
| Sep 28, 2026 | $15.49 | $15.7599 | $15.20 | $15.54 | 533.57K |
| Sep 25, 2026 | $15.32 | $15.65 | $15.15 | $15.49 | 635.49K |
| Sep 24, 2026 | $15.48 | $15.64 | $15.00 | $15.28 | 497.48K |
| Sep 23, 2026 | $15.66 | $15.88 | $15.23 | $15.51 | 503.36K |
| Sep 22, 2026 | $15.57 | $15.73 | $15.385 | $15.67 | 439.37K |
| Sep 21, 2026 | $15.44 | $15.50 | $15.13 | $15.42 | 315.68K |
| Sep 18, 2026 | $15.22 | $15.555 | $14.97 | $15.44 | 1.01M |
| Sep 17, 2026 | $15.55 | $15.62 | $15.32 | $15.37 | 558.68K |
| Sep 16, 2026 | $15.68 | $15.92 | $15.41 | $15.46 | 469.64K |
| Sep 15, 2026 | $15.44 | $15.79 | $15.20 | $15.68 | 661.54K |
| Sep 14, 2026 | $15.32 | $15.55 | $15.11 | $15.51 | 389.33K |
| Sep 11, 2026 | $15.44 | $15.47 | $15.065 | $15.27 | 341.96K |
| Sep 10, 2026 | $15.21 | $15.46 | $15.01 | $15.24 | 238.75K |
| Sep 9, 2026 | $15.09 | $15.36 | $14.935 | $15.32 | 328.78K |
Latest ANGO news
The latest Smart Investors Daily articles mentioning ANGO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ANGO research
Overview
Company profile and research snapshot.
Company profile
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2026 | Canaccord Genuity | Buy | — |
| Apr 6, 2026 | Freedom Broker | Buy | — |
| Apr 6, 2026 | Canaccord Genuity | Buy | — |
| Oct 3, 2025 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 2, 2026
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
LATHAM, N.Y., October 02, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York have been selected as an ALPHA-PE Research Fund award recipients. The independent, investigator-led study, supported in partnership with The PERT C
Yahoo · Sep 28, 2026
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
LATHAM, N.Y., September 28, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.
Yahoo · Aug 13, 2026
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
